HSBC cut Novo Nordisk to ‘Hold’ after its EVOKE Alzheimer’s trials showed no slowing of disease progression versus placebo.

Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s ...

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...

The results from the two trials of early-stage Alzheimer's patients, called EVOKE and EVOKE+, are another setback for the ...

Mayo Clinic researchers have developed a new tool that can estimate a person's risk of developing memory and thinking ...

We break down the current state of frontotemporal dementia, from bvFTD to PPA, and why 'promising' therapies are still far ...

Compared with the lowest quintile of midlife physical activity, the top two quintiles were associated with 40% lower ...

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main ​goal in late-stage trials ...